Our innovation strategy: putting the patient first
At Boehringer Ingelheim, we have the patient at the core of everything we do. We focus on identifying the truly relevant disease mechanism and then we use the most adequate therapeutic modality to address it. And we always follow the science. We remain humble in front of the biology, which is always more complex than what we think. We are prepared to build on unexpected findings as a way to generate truly disruptive innovation, within and also beyond our current research and development (R&D) focus.
Our approach to research and development
Disease never rests. So neither do we. Learn about how we are driving innovation in research and development, with the patient at the core of everything with do.
Our guiding principles
To optimally support the patient, we build on our three guiding principles:
- Build on our strengths: For example, we are building on the expertise we have accumulated in disease areas such as respiratory and cardiovascular diseases
- Capture synergies and build bridges: This is illustrated by our scientific platforms for immune modulation and fibrosis, with a broad spectrum of potential application across various disease areas.
- Incorporate emerging science within and beyond our current research and development focus to prepare timely entry into a new field.
This is possible based on our people and their passion to help patients and lead the science, our external partners and our sustainable innovation, building on more than 130 years history, during which we were able to continuously reinvent ourselves.
Related Content
Drug Discovery
Clinical Pipeline
